Lilly, Boehringer's Jardiance has heart failure trial setback
Dec. 13, 2019
Boehringer Ingelheim and Eli Lilly announced failing results in two trials evaluating Jardiance in adults with chronic heart failure.
In both the EMPERIAL-Reduced and EMPERIAL-Preserved trials, there was no significant change from baseline to week 12 in exercise ability with Jardiance versus placebo, as measured by the six-minute walk test.
In January 2011, Boehringer Ingelheim and Eli Lilly formed an alliance that centers on compounds representing several of the largest diabetes treatment classes. As part of this alliance, Jardiance was approved by the FDA in 2014, and is already a blockbuster in the treatment of Type 2 diabetes.
Read the press release
